JCR Closes ArmaGen Buyout, Gaining IP Rights on Blood-Brain Barrier-Penetrating Technology

April 21, 2020
JCR Pharmaceuticals said on April 20 that it has completed the acquisition of ArmaGen, making the San Diego biotech its wholly-owned subsidiary. They do not disclose the purchase price for the buyout. JCR is engaged in the development of therapies...read more